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INTRODUCTION
Heart – Structure1
The heart is a hollow, four-chambered (two atria; two ventricles) muscular 
organ that is specialized for pumping blood through the vessels of the body. It is 
located in the mediastinum where it is surrounded by a tough fibrous membrane 
called the pericardium. The parietal pericardium is a loose sac composed of an 
outer fibrous layer that protects the heart and an inner serous layer that secretes 
pericardial fluid. The visceral pericardium is a serous membrane that makes up 
the outer layer of the wall of the heart (the epicardium). The space between the 
parietal pericardium and the visceral pericardium is called the pericardial cavity.  
Pericardial fluid is found within this cavity and functions to lubricate the surface of  
the heart.
Layers of the heart
The heart is composed of three layers from superficial to deep:
 Epicardium   : Outer serous layer.
 Myocardium  : Middle muscular layer; thickest layer.
 Endocardium : Inner epithelial layer.
 
Electrical conduction system of the heart2 
Inherent firing rate is the rate at which the SA node or another pacemaker 
site normally generates electrical impulses.
A.  SA Node - Sinoatrial node
1.  Dominant or primary pacemaker of the heart.
2.  Inherent rate 60 – 100 beats per minute.
3.  Located in the wall of the right atrium, near the inlet of the superior vena cava.
4.  Once an impulse is initiated, it usually follows a specific path through the heart, and 
usually does not flow backward
B.  Intra-atrial tracts - Bachmann's bundle
As the electrical impulse leaves the SA node, it is conducted through the left atria by way 
of the Bachmann's bundles, through the right atria, via the atrial tracts.
C.  AV Junction - Made up of the AV node and the bundle of His.
1.  AV node
a)  Is responsible for delaying the impulses that reach it.
b) Located in the lower right atrium near the interatrial    septum.
c) Waits for the completion of atrial emptying and ventricular filling, to    allow the 
cardiac muscle to stretch to it's fullest for peak cardiac output.
d)  The nodal  tissue  itself  has  no pacemaker  cells,  the  tissue  surrounding  it 
(called the junctional  tissue) contains pacemaker cells  that  can fire  at  an 
inherent rate of 40 – 60 beats per minute.
2.  Bundle of His
a)  Resumes rapid conduction of the impulses through the ventricles.
b)  Makes up the distal part of the AV junction then extends into the ventricles 
next to the interventricular septum.
c)  Divides into the Right and Left bundle branches.
3.  Purkinje Fibers
a)  Conduct impulses rapidly through the muscle to assist in depolarization  and 
contraction.
b)  Can also serve as a pacemaker, discharges at an inherent rate of 20 – 40 
beats per minute or even more slowly.
c)  Are  not  usually  activated  as  a  pacemaker  unless  conduction  through the 
bundle of His becomes blocked or a higher pacemaker such as the SA node 
or AV junction do not generate an impulse.
d)  Extends form the bundle branches into the endocardium and deep into the 
myocardial tissue.
Figure 1: Electrical conduction system of the heart
 
Death by Medicine
Many new pharmaceutical agents have been withdrawn from the market 
or  severely  restricted  to  specific  indications  because  of  unexpected  adverse 
events, including fatalities. Cardiac, hepatic, and hematological abnormalities are 
the major causes of withdrawal of drugs or restriction in their labeling.  A short 
review of medical peer-review journals and government health statistics shows 
that modern medicine imposes more harm than benefits.  Of note, a group of 
researchers meticulously reviewed the statistical evidence and their findings are 
absolutely shocking. These researchers have authored a paper titled “Death by 
Medicine” that  presents  compelling  evidence  that  today’s  medical  system 
frequently causes more harm than good3. This fully referenced report shows that 
the  deaths  caused  by  conventional  medicine  were  chiefly  due  to  the  heart  
disease. Hence, recent regulatory developments are thrusting cardiac safety to 
the forefront of clinical development.  
Cardiotoxic Drugs 
The major culprits for cardiotoxicity include: 
• Cytostatics (anti-neoplastic agents)
• Immunomodulators
• Calcium channel blocking agents
• Antidepressants
• Non-steroidal anti-inflammatory drugs
• Anti-arrhythmics 
• β-adrenergic blockers 
• Anesthetics.  
Cytostatics at the front4
Since cancer is a leading cause of  mortality worldwide,  the number of 
therapeutic modalities available  for  the treatment of  neoplastic  processes has 
increased. This has resulted in a large number of patients being exposed to a 
wide  variety of  cancer  therapy.  Historically,  it  has  been  well  recognized  that 
antineoplastic agents may have adverse effects on multiple  organs and normal 
tissues. The most commonly associated toxicities  occur in tissues composed of 
rapidly dividing cells (e.g. hematopoietic cells) and may  spontaneously reverse 
with minimal long-term toxicity. However, the myocardium consists of cells that 
have limited regenerative capability, which may render the heart susceptible to 
permanent or  transient  adverse  effects  from  chemotherapeutic  agents.  Such 
toxicity encompasses a heterogeneous group of disorders, ranging  from relatively 
benign  arrhythmias  to  potentially  lethal  conditions  such  as  myocardial 
ischemia/infarction and cardiomyopathy. In some instances, the pathogenesis of 
these toxic effects has been elucidated, whereas in others the precise etiology 
remains unknown. In this context, an ample literature data suggest that “oxidative 
stress” plays a pivotal role in the cardiotoxicity of cytotoxic drugs5.
Oxidative Stress 
Oxidative  stress,  implicated  in  the  pathogenesis  of  a  wide  variety  of 
clinical disorders, refers to the cytological consequence of a mismatch between 
the production of free radicals and the ability of the cell to defend against them. 
Oxidative stress can thus occur when the generation of free radicals increases or 
the  capacity  to  scavenge  free  radicals  and  repair  of  oxidatively  modified 
macromolecules decreases, or both6. This imbalance leads to the accumulation 
of oxidatively modified molecules, referred to as reactive oxygen species (ROS).
Types of Reactive Species
• Reactive Oxygen Species (ROS)
• Oxygen-centered radicals 
 Superoxide anion (·O2–)
 Hydroxyl radical (·OH)
 Alkoxyl radical (RO·)
 Peroxyl radical (ROO·) 
• Oxygen-centered non-radicals
 Hydrogen peroxide (H2O2)
 Singlet oxygen (1O2)
• Reactive Nitrogen species (RNS)
 Nitric oxide (NO·)
 Nitric dioxide (NO2·)
 Peroxynitrite (OONO–). 
The presence of free radicals in biological materials was discovered 50 
years ago7. Soon thereafter, Harman described free radicals as a Pandora’s Box 
of evils that may account for gross cellular damage, mutagenesis, cancer, and, 
last but not least, the degenerative process of biological aging.  
Mitochondria and ROS8 
Aerobic energy metabolism is dependent on oxidative phosphorylation, a 
process by which the oxidoreduction energy of mitochondrial electron transport 
(via a multicomponent NADH dehydrogenase enzymatic complex) is converted to 
the high-energy phosphate bond of ATP. O2 serves as the final electron acceptor 
for  cytochrome-c  oxidase,  the  terminal  enzymatic  component  of  this 
mitochondrial enzymatic complex that catalyzes the four-electron reduction of O2 
to H2O. Partially reduced and highly reactive metabolites of O2  may be formed 
during  these  (and  other)  electron  transfer  reactions.  These  O2 metabolites 
include superoxide anion (·O2–) and hydrogen peroxide (H2O2), formed by one- 
and  two-electron  reductions  of  O2,  respectively.  In  the  presence of  transition 
metal ions, the even more reactive hydroxyl radical (·OH) can be formed. These 
partially  reduced metabolites  of  O2 are  often  referred  to  as  “reactive  oxygen 
species” (ROS) due to their higher reactivities relative to molecular O2. ROS from 
mitochondria and other cellular sources have been traditionally regarded as toxic 
by-products of metabolism with the potential to cause damage to lipids, proteins, 
and DNA.
 Oxygen Paradox
Under  physiological  conditions,  approximately  1–3%  of  the  molecular 
oxygen (dioxygen; O2) consumed by the body is converted into superoxide and 
other ROS. Thus, although molecular oxygen is absolutely essential for aerobic 
life, it can be toxic under certain conditions. This ‘double-edged sword’ aspect of  
oxygen may be regulating longevity and the phenomenon has been termed as 
“oxygen paradox”9.  
ROS in Cell Signaling
 Accumulating  evidence  suggests  that  ROS  are  not  only  injurious  by-
products of cellular metabolism but also essential participants in cell  signaling 
and regulation10,11.  Although this role for ROS is a relatively novel  concept in 
vertebrates, there is strong evidence of a physiological role for ROS in several  
non-mammalian systems. The apparent paradox in the roles of ROS as essential 
biomolecules in the regulation of cellular functions and as toxic by-products of 
metabolism may be, at least in part, related to differences in the concentrations 
of ROS produced.
 
Analogy of ROS and Nitric Oxide8 
The paradoxical behavior of ROS is analogous to the effects of nitric oxide 
(NO·), which has both regulatory functions and cytotoxic effects depending on 
the enzymatic source and relative amount of NO· generated. NO· functions as a 
signaling molecule mediating vasodilation when produced in low concentrations 
by the constitutive isoform of nitric oxide synthase (NOS) in vascular endothelial 
cells and as a source of highly toxic oxidants utilized for microbicidal killing when 
produced  in  high  concentrations  by  inducible  NOS  (iNOS)  in  macrophages. 
Indeed, all  phagocytic  cells have a well-characterized ·O2–-generating plasma 
membrane oxidase capable of producing the large amounts of ROS required for 
its function in host defense.
NO is synthesized enzymatically from L-arginine by NO synthase (NOS).
  
Lipid peroxidation (LPO)
ROS  exert  their  cytotoxic  effect  by  peroxidation  of  membrane 
phospholipids leading to change in permeability and loss of membrane integrity. 
Lipid oxidation is a free-radical chain reaction, and reactive oxygen species can 
accelerate  lipid  oxidation.  Cell  membranes  are  phospholipid  bilayers  with 
extrinsic proteins and are the direct  target of  lipid oxidation. Malondialdehyde 
(MDA), one of the lipid oxidation products, can react with the free amino group of 
proteins, phospholipid, and nucleic acids leading to structural modification, which 
induce dysfunction of immune systems. A high level of lipid peroxidation products 
can be detected in cell degradation after cell injury or disease.
L-arginine  + O2 +   NADPH → L-citrulline + NO + NADP+
ROS and Apoptosis12
1. Induction and execution of apoptosis
Apoptosis  is  a  special  form  of  programmed  cell  death  that  plays  an 
indispensable  role  in  the  development  and  homeostasis  of  multicellular 
organisms.  The potential  for  mitochondrial  ROS to mediate cell  signaling has 
gained  significant  attention  in  recent  years,  particularly  with  regard  to  the 
regulation of apoptosis. An increase in cellular ROS production is often observed 
in  apoptotic  processes  triggered  by  various  stimuli.  Also,  high  ROS 
concentrations induce apoptotic cell death in various cell types, suggesting that  
ROS contribute to cell death whenever they are generated in the context of the 
apoptotic  process.  Exposure  of  T-lymphocytes  to  relatively  moderate 
concentrations of hydrogen peroxide was found to induce a CD95-independent 
apoptotic process that requires mitochondrial ROS production and the activation 
of NF-kB. This underscores the need to transfer lymphocytes to more reducing 
conditions for the development of immunological effector functions. 
2. NO-dependent apoptosis
NO-dependent  apoptosis  has  been  observed  in  several  experimental 
models  and  certain  clinical  pathologies.  Induction  of  apoptosis  by  NO  is 
associated with a decrease in the concentration of cardiolipin, decreased activity 
of  the  mitochondrial  electron  transport  chain,  and  release  of  mitochondrial 
cytochrome  c  into the cytosol.  However,  some cell  types,  such as endothelial 
cells  from  the  microvasculature,  are  extremely  resistant  to  the  induction  of 
apoptosis by NO, and low concentrations of NO provide protection from apoptotic 
cell death in various cell types by inhibiting certain caspases. High intracellular 
glutathione  levels  are  associated  with  increased  resistance  to  NO-mediated 
apoptosis.
3. Induction of cell death by TNF-α
TNF- α induces cell death in many types of tumor cells and has been used 
in  model  systems  for  studies  of  the  molecular  mechanisms of  cell  death.  In 
transformed  cell  lines  TNF-α  induces  endogenous  ROS  production  by 
mitochondria. Whether and how these ROS contribute to the induction of cell  
death depends on the signaling and execution pathways that are activated. In 
leukocytes  and fibroblasts,  TNF- α  induces the  release of  superoxide  by  the 
activation  of  membrane-bound  NADPH  oxidases.  This  process  induces 
proliferation or cell death depending on the condition of the ROS-producing cell.  
There is evidence to suggest that tumor necrosis factor (TNF)-α and interleukin 
(IL)-1-induced generation of mitochondrial ROS has been implicated in apoptotic 
cell death. It has also been suggested that the mitochondria may function as an 
“O2 sensor” to mediate hypoxia-induced gene transcription.
Figure 2: Cellular response to oxidative stress. Different levels of oxidative 
stress cause different outcomes in cells.
Apoptosis and Necrosis13
Cells  must  constantly  die  to  ensure  the  normal  development  of  an 
organism and to maintain the balance between the generation and loss of cells 
(homeostasis). This activity is regulated by programmed cell death, a type of “cell  
suicide”, the morphological correlative of which is apoptosis. Apoptosis plays an 
important role for the correct function of the immune system.
Apoptosis  is  a  very  subtle  process.  The  first  signs  of  apoptosis  are 
chromatin  condensation  and  shrinkage  of  the  cell.  The  cell  membrane  that 
develops small bulges in a process known as zeiosis (blebbing). The cell that 
begins to expel its contents into vesicles, some of which contain parts of the 
fragmented and condensed (pyknotic)  cell  nucleus. The vesicles are ingested 
and  degraded  by  macrophages.  Since  the  cytoplasmic  enzymes  and  toxic 
metabolites  are  always  surrounded  by  membranes,  no  inflammatory  reaction 
occurs. 
Cell necrosis, on the hand, occurs as the result of severe injuries due, for 
example,  to  burns,  oxygen  deficiency  (e.g.,  heart  attack),  and  trauma.  In 
necrosis, the cell membrane loses its integrity. As a result, the cell starts to swell,  
and the contents, together with a number of toxic substances are released into 
the surrounding tissue, thus inducing an inflammatory reaction. 
Figure 3: Differences between Necrosis and Apoptosis
The potential role of NO in cardiac pathology  
Fogli  et al.14 proposed the plausible link between elevated NO level and 
the heart  pathology.  Increased iNOS expression has been reported in human 
cardiac disease including dilated cardiomyopathy,  heart failure, and contractile 
dysfunction of the left ventricle after heart transplantation. It is conceivable that 
the balance between the physiologic and pathologic production of NO may be 
critical  in  regulating  cardiac  function  and  preserving  cardiomyocyte  integrity 
whereas the pathological switch may be expected when there is an abnormal 
level of NO production, and/or when there is an excess of superoxide anion. For  
example,  excessive  production  of  superoxide  in  reperfused  myocardium  can 
inactivate NO, and this may contribute to the coronary vasoconstriction. On the 
other  hand,  excess  superoxide  reacts  with  NO  enhancing  the  production  of 
peroxynitrite,  a  potent  oxidant  that  is  able  to  oxidize  lipids,  nitrate  tyrosine 
residues  on  proteins,  and  decompose  to  toxic  products  including  the  highly 
reactive  hydroxyl  radicals.  Thus,  the  abundant  synthesis  of  NO  and/or  O2.- 
generates a free radical cascade that, in turn, may disrupt key cellular targets in 
the heart and represent a cause of cardiomyopathy. In this regard, evidence is 
available  demonstrating  a  significant  contribution  of  increased  RNS/ROS 
production  and protein  nitration  in  the  progression  of  cardiovascular  disease. 
Finally,  the  relevance  of  mitochondria  in  the  damaging  effect  of  NO  further 
support  the  role  of  ONOO–  in  NO-mediated  apoptotic  damage  and 
cardiotoxicity15-17.  iNOS  up-regulation  by  cytokines  increases  apoptosis  in 
cultured myocytes by a process that is independent of guanylate cyclase/cGMP 
pathway and associated with the shift in the cellular balance toward proapoptotic 
Bak  vs.  antiapoptotic  Bcl-xL18,19.  Thus,  the  available  data  demonstrate  the 
multiplicity of NO molecular targets and point to the important role of the disarray 
of NO homeostasis in cardiac cell injury in various heart diseases.
 
Cellular antioxidant defensive system20
To protect against the potentially damaging effects of ROS, mammalian 
cells encompass an impressive gamut of antioxidant defensive system which 
includes:
 Superoxide dismutases (SOD)
 Catalase (CAT)
 Glutathione peroxidase (GPx)
 Glutathione-S-transferase (GST)
 Glutathione disulphide reductase (GR)
 Glutathione (GSH)
Superoxide dismutases (SOD)
Superoxide dismutases (SOD) were the first genuine ROS-metabolizing 
enzymes discovered. In eukaryotic cells, O2·– can be metabolized to hydrogen 
peroxide by two metal-containing SOD isoenzymes:
♥ A tetrameric Mn-SOD present in mitochondria and
♥ A dimeric Cu/Zn-SOD present in the cytosol.  
Catalases (CAT) 
Antioxidative  role  of  catalase  is  to  lower  the  risk  of  hydroxyl  radical 
formation from H2O2 via the Fenton-reaction catalyzed by Cu or Fe ions.
Glutathione peroxidases (GPx):
There are at least four different GPx in mammals (GPx1–4), all of them 
containing  selenocysteine.  All  glutathione  peroxidases  may  catalyze  the 
reduction of H2O2 using glutathione as substrate.  They can also reduce other 
peroxides (e.g., lipid peroxides in cell membranes) to alcohols. 
Other Glutathione-related systems 
Hydrogen  peroxide  is  reduced  by  glutathione  peroxidases  (GPx)  by 
oxidation  of  two  molecules  of  glutathione (GSH) forming glutathione disulfide 
(GSSG) that subsequently can be reduced by glutathione reductase (GR) under 
consumption  of  NADPH. Glutathione also  reduces glutaredoxins  (Grx)  that  in 
their turn reduce various substrates. Specific for glutaredoxins is the reduction of 
glutathione mixed disulfides  such as  glutathionylated  proteins.  Glutathione S-
transferases (GST) catalyze the conjugation of glutathione with other molecules, 
thereby functioning as an intermediate step in the detoxification of miscellaneous 
toxic substances. 
Figure 4: Schematic summary of the major glutathione-associated 
antioxidant systems
 
Figure 5: Simplified non-stoichiometric scheme of oxidative and 
antioxidative systems in cells
Superoxide is produced in significant amounts intracellularly, both in the 
cytosol via flavin-containing enzymes, and in mitochondria, mainly due to escape 
of  electrons from the  respiratory  chain.  Two molecules  of  superoxide  rapidly 
dismutate, either spontaneously or via superoxide dismutases to dioxygen and 
hydrogen  peroxide,  the  latter  permitting  flux  of  ROS  between  cellular 
compartments. Hydrogen peroxide can be enzymatically metabolized to dioxygen 
and water by a number of different enzyme systems or converted to the hydroxyl  
radical,  which  is  extremely  reactive,  via  a  chemical  reaction  catalyzed  by 
transition metals.
 
Antineoplastic agents
The anticancer  drugs  either  kill  cancer  cells  or  modify  their  growth.  A 
tumor (neoplasm) consists of cells that proliferate independently of the body’s 
inherent “building plan.” A malignant tumor (cancer) is present when the tumor 
tissue destructively invades healthy surrounding tissue or when dislodged tumor 
cells form secondary tumors (metastases) in other organs21. 
Cancer chemotherapeutic modalities22
A. Curative therapy 
In curative therapy, the malignant cells are completely removed. This is 
now possible in:
 Acute leukemia
 Retinoblastoma
 Lymphosarcoma
 Testicular teratoma
 Hodgkin’s disease
 Mycosis fungoides
B. Palliative therapy
When curing is not possible, attempts can be made to slow tumor growth 
and thereby prolong the patient’s life or improve quality of life, which is termed as 
“palliative therapy”. Chemotherapy is faced with the problem that the malignant 
cells are endogenous and are not endowed with special metabolic properties.
C. Adjuvant therapy
Drugs are used to mop up any residual malignant cells after surgery or 
radiotherapy. This is routinely employed now.
Classification of the Anticancer Drugs23
  
I. Alkylating agents
A. Nitrogen mustards
1. Cyclophosphamide
2. Chlorambucil 
3. Melphalan 
4. Ifosfamide  
B. Alkyl sulfonates
1. Busulfan 
C. Nitrosoureas
1. Carmustine 
2. Streptozocin 
D. Ethylenimines
1. Thiotepa
E. Triazenes
1. Dacarbazine 
II. Antimetabolites
A. Folate antagonist
1. Methotrexate 
B. Purine analogues
1. Thioguanine 
2. Mercaptopurine 
C. Pyrimidine analogues
1. Cytarabine 
2. Fluorouracil 
III. Antibiotics
A. Anthracyclines
1. Doxorubicin hydrochloride (Adriamycin)
2. Daunorubicin 
IV. Plant-derived products
A. Vinca alkaloids
1. Vincristine 
2. Vinblastine 
B. Epipodophyllotoxins
1. Etoposide 
2. Teniposide 
V. Enzymes
A. L-Asparaginase 
VI. Hormonal agents
A. Glucocorticoids
B. Estrogens, antiestrogens
1. Tamoxifen citrate 
C. Androgens, antiandrogens
D. Progestins
E. Luteinizing hormone–releasing hormone (LH-RH) antagonists
F. Octreotide acetate 
VII. Miscellaneous agents
A. Hydroxyurea 
B. Procarbazine 
C. Cisplatin 
D. Carboplatin  
VIII. Monoclonal antibodies
IX. Immunomodulating agents
A. Levamisole 
B. Interferons
C. Interleukins
General toxicological properties of anticancer drugs
Most of the drugs used in cancer treatment have a therapeutic index that 
approaches unity, exerting toxic effects on both normal and tumor tissues even at 
optimal dosages. This lack of selective toxicity is the major limiting factor in the 
chemotherapy  of  cancer.  Rapidly  proliferating  normal  tissues,  such  as  bone 
marrow,  gastrointestinal  tract,  and  hair  follicles,  are  the  major  sites  of  acute 
toxicity of these agents. In addition, acute toxicities like cardiotoxicity, urothelial 
toxicity,  and  even  chronic  and  cumulative  toxicities  may  occur.  The  most 
commonly encountered toxicities of antineoplastic agents are described in the 
following section:
• Bone marrow toxicity
• Gastrointestinal tract toxicity
• Hair follicle toxicity
• Cardiotoxicity.
Bone marrow toxicity
Chemotherapy  may  result  in  the  destruction  of  actively  proliferating 
hematopoietic precursor cells. White blood cell and platelet counts may in turn be 
decreased, resulting in an increased incidence of life-threatening infections and 
hemorrhage. The risk of serious infections has been shown to increase greatly 
when  the  peripheral  blood  granulocyte  count  falls  below  1000  cells/mm3.  A 
chronic bone marrow toxicity or hypoplastic state may develop after long-term 
treatment  with  nitrosoureas,  other  alkylating  agents,  and  mitomycin  C.  Thus, 
patients  frequently  will  require  a  progressive  reduction  in  the  dosages  of 
myelosuppressive  drugs  when  they  are  undergoing  long-term  therapy,  since 
such treatment may result in chronic pancytopenia.
Gastrointestinal tract toxicity
The  nausea  and  vomiting  frequently  observed  after  anticancer  drug 
administration are actually thought to be caused by a stimulation of the vomiting 
center or chemoreceptor trigger zone in the central nervous system (CNS) rather 
than  by  a  direct  gastrointestinal  effect.  These  symptoms  are  ameliorated  by 
treatment with phenothiazines and other centrally acting antiemetics. Commonly, 
nausea begins 4 to 6 hours after treatment and lasts 1 or 2 days. Although this 
symptom is distressing to patients, it is rarely severe enough to require cessation 
of therapy. Anorexia and alterations in taste perception also may be associated 
with chemotherapy. 
The  serotonin  antagonist  ondansetron  has  proved  effective  in  the 
prevention  of  nausea  and  vomiting  due  to  chemotherapy.  Damage  to  the 
normally proliferating mucosa of the gastrointestinal tract may produce stomatitis, 
dysphagia,  and  diarrhea  several  days  after  treatment.  Oral  ulcerations, 
esophagitis, and proctitis may cause pain and bleeding.
Hair follicle toxicity
Most  anticancer  drugs  damage  hair  follicles  and  produce  partial  or 
complete  alopecia.  Patients  should  be  warned  of  this  reaction,  especially  if 
paclitaxel,  cyclophosphamide,  doxorubicin,  vincristine,  methotrexate,  or 
dactinomycin  is  used.  Hair  usually  regrows  normally  after  completion  of 
chemotherapy.
Cardiotoxicity24 
Cardiotoxicity occurs during therapy with several cytotoxic drugs and may 
be  the  dose  limiting  factor  in  cancer  treatment  and  hence  tumour  response. 
Furthermore, cardiotoxicity can also be responsible for long term side effects and 
may cause severe morbidity in surviving cancer patients, which may be relevant 
especially in pediatric oncology. Cardiotoxicity from cytotoxic treatment is known 
to have a high prevalence. Cardiotoxicity includes a wide range of cardiac effects 
from small  changes in  blood pressure and arrhythmias to cardiomyopathy.  In 
literature  different  mechanisms  of  chemotherapy  induced  cardiotoxicity  are 
postulated including cellular damage due to the formation of free oxygen radicals 
and  the  induction  of  immunogenic  reactions  with  the  presence  of  antigen 
presenting cells in the heart. Moreover, the influence of the cytotoxic agent on 
certain phospholipids, especially cardiolipin, may also explain the development of 
cardiotoxicity. The anthracyclines, such as doxorubicin and epirubicin, are potent 
cytotoxic  drugs but  their  clinical  use is  often  limited  by  their  cardiotoxic  side 
effects.  Other  cytotoxic  drugs  that  have  reported  cardiotoxicity  include 
cyclophosphamide,  5-fluorouracil,  capecitabine,  mitoxantrone,  cisplatin,  the 
taxoids  paclitaxel  and  docetaxel  and  newer  drugs  such  as  the  monoclonal 
antibody trastuzumab.
Plants and human health
For centuries people have used plants for healing. Plant products – as 
parts of foods or botanical potions and powders – have been used with varying 
success to cure and prevent diseases throughout history. Written records about 
medicinal  plants  date  back  at  least  5000  years  to  the  Sumerians25,  and 
archeological records suggest even earlier use of medicinal plants.
The US Federal Food and Drug Administration (FDA) recently published 
guidance  for  standardized  multifunctional  and  multicomponent  plant  extracts, 
referred to as botanical drugs, thus making it possible to market these products 
under the New Drug Application (NDA) Approval Process26. In response to the 
public demand for trustworthy and effective alternatives to new chemical entity 
(NCE) pharmaceuticals, the agency proposed abbreviated preclinical and clinical 
testing protocols for botanical drugs derived from plants with a safe history of 
human use. This has enabled US industrial and academic scientists to become 
involved in botanical drug R&D efforts. Botanical drugs are fully accepted and 
widely prescribed in China, Japan, India and other Asian and African countries. 
In  addition,  some  countries  in  Europe,  such  as  Germany,  allow  physicians 
prescribe botanical drugs.
Botanical dietary supplements
Botanical  dietary  supplements  – also  called  botanical  nutraceuticals  or 
herbals – can be best defined as plant-derived materials with medical benefits 
aimed  at  disease  prevention  or  treatment  that  go  beyond  satisfying  basic 
nutritional requirements. 
Common botanical dietary supplements sold in the USA and their 
therapeutic indications27 
Echinacea purpurea L.angustifolia, 
DC. and pallida Nutt.
- Respiratory infections,
  Immunostimulant.
Panax ginseng, L.A. Mey (ginseng) - Fatigue and stress, high cholesterol, 
diabetes, gastro-intestinal disorders.
Serenoa repens (W. Bartam) Small
(saw palmetto)
 - Benign prostatic hyperplasia (BPH), 
inflamations, impotence.
Ginkgo biloba L. - Dementia, cognitive decline, mental     
  fatigue.
Hypericum perforatum L. 
(St John's wort)
- Mild and moderate depression,
  Epilepsy.
Valeriana officinalis L. (valerian) - Sleep improvements, anxiety,
  Hypertension.
Allium sativum L. (garlic) 
(contd.) 
Allium sativum L. (garlic)
- Cancer, high cholesterol, diabetes,
  arteriosclerosis, hypertension,
  
respiratory infections.
Hydrastis canadensis L. 
(goldenseal)
- Diarrhea, respiratory and
  Gastrointestinal infections,
  Constipation.
Matricaria chamomilla L.
(German chamomile)
- Intestinal disorders, wound healing, 
inflammations, anxiety.
Silybum marianum gaertn.
(milk thistle)
- Liver disorders, lactation problems.
Trigonella foenum-graecum L.
(fenugreek)
- Diabetes, loss of appetite, skin 
  Inflammation.
Tanacetum –parthenium Schultz-
Bip.
(feverfew)
- Migraines, inflammation.
Ephedra sinica Stapf. 
(Ephedra, Ma Huang)
- Stimulant, obesity, asthma,
  congestion, fluid retention.
Cimicifuga racemosa Nutt.
(black cohosh)
- Premenstrual symptoms,
  dysmenorrhea, menopausal
  symptoms.
DRUG PROFILE
Cyclophosphamide
Properties28,29
 Cyclophosphamide  is  an  alkylating  agent  and  a  derivative  of  nitrogen 
mustard. 
 It is an odorless, fine white crystalline powder.
 Molecular weight is 261.1 and melting point is 49.5°C to 53°C.
 It  is  soluble in water  and ethanol;  slightly soluble in benzene, ethylene 
glycol, carbon tetrachloride, and dioxane; and sparingly soluble in diethyl 
ether and acetone. Its log octanol-water partition coefficient is 0.63. 
 It reacts with strong oxidizing agents.
 It is sensitive to moisture and light, and is hydrolyzed in aqueous solutions 
above 30°C.
Indications
► Cyclophosphamide is used as a drug to treat cancer and other medical 
conditions. In chemotherapy, it may be used alone, but more frequently is 
used concurrently or sequentially with other anticancer drugs. 
► It is used to treat malignant lymphoma, multiple myeloma (bone-marrow 
cancer), leukemia, breast and ovarian cancer, neuroblastoma (childhood 
nerve-cell  cancer),  retinoblastoma (childhood cancer of  the retina),  and 
mycosis fungoides (lymphoma of the skin)30-32. 
► Cyclophosphamide also is used as an immunosuppressive agent following 
organ transplants 
► It  is  used  to  treat  autoimmune disorders  such  as  rheumatoid  arthritis, 
Wegener’s  granulomatosis  (an inflammation  of  the blood vessels),  and 
nephrotic syndrome (a kidney disorder) in children33. 
Proprietary names34 
 Ledoxan®     - Dabur Pharmaceuticals Ltd.
 Cyphos®      - Intas Pharmaceuticals Pvt. Ltd.
 Eldamide®   - Elder Pharmaceuticals Pvt. Ltd.
 Neophos®    - Cipla Ltd.
 Oncophos®  - Cadila Pharmaceuticals Ltd.
 Cydoxan®     - Alkem Laboratories Ltd. 
Preparations34
 Cyclophosphamide  is  available  in  the  strength  of  50-mg  tablet 
preparations.  
 In a crystalline hydrate form for injection in strengths of 100 to 2,000 mg.
Dosage34
 Doses used in medical treatment depend on the patient and the specific 
disease. 
 Cyclophosphamide may be given orally (in 25- or 50-mg tablet form) or by 
i.v. injection (100-mg, 200-mg, 500-mg, 1-g, or 2-g vials). 
 The initial  treatment for cancer patients with  no hematologic deficiency 
may be 40 to 50 mg/kg of body weight in divided i.v. doses over two to five 
days, 10 to 15 mg/kg every seven to ten days, or 3 to 5 mg twice a week. 
 The adult dosage for tablets typically is 1 to 5 mg/kg of body weight per 
day for both initial and maintenance treatment. 
 For nonmalignant diseases, an oral dose of 2.5 to 3 mg/kg per day is 
administered for 60 to 90 days32.
Contraindications
 Bladder haemorrhage
 Pregnancy
 Lactation.
Precautions
 Diabetics
 Liver, heart or kidney impairment
 Geriatrics
 Pediatrics.
Aldehyde
oxidase
Adverse effects
 Alopecia
 Myelosuppression
 GI Toxicity
 Cardiotoxicity
 Haemorrhagic cystitis
 Pulmonary toxicity
 Infertility
 Carcinogenesis
Figure 6: Bioactivation pathway of cyclophosphamide
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PLANT PROFILE
Taxonomic classification
Plant name : Ficus hispida Linn.
Division : Magnoliophyta
Class : Magnoliopsida
Subclass : Rosidae
Order : Rosales
Family : Moraceae (Mulberry)
Genus : Ficus
Species : hispida
Vernacular names
Bengali  - Dumoor
English  - Rough-leaved fig
Hindi     - Gobla
Tamil     - Peyatti
Telugu   - Bhramhamedi.
Distribution
Ficus  hispida  Linn.  Is  widely  distributed  throughout  India,  Sri  Lanka, 
Myanmar,  sothern  regions  of  the  People’s  republic  of  China,  New  Guinea, 
Thailand, Vietnam, Nepal and Queensland in Australia. 
ACROLEIN
(cytotoxic)4-KETO 
CYCLOPHOSPHAMIDE
(inactive)
Habitat
F.  hispida is  a  shrub or  moderate  sized tree  that grows  in  secondary 
forests, open lands, and riverbanks, at an altitude of 450-1200 m.
Description36
Coarsely hairy;  dioecious. Stipules usually 4 and decussate on leafless 
fruiting  branchlets,  ovate-lanceolate.  Leaves  opposite;  petiole  with  short  thick 
hairs; leaf blade ovate, oblong, or obovate-oblong, thickly papery, abaxially with  
coarse gray hairs,  adaxially rough and with  short thick hairs,  margin entire or 
bluntly toothed, apex acute to mucronate.
Uses in Indigenous medicine37,38
 Different  plant  parts  are  used  in  skin  diseases,  leucoderma,  and 
jaundice and as anti-poisonous.
 Leaves  are  used  as  an  anti-diarrhoeal,  antitussive,  antipyretic, 
astringent, anti-inflammatory,  haemostatic, anti-ulcer, vulnerary and 
in treatment of liver disorders.
 Bark  as  emetic,  anti-diarrhoeal  and  in  the  treatment  of  diabetes 
mellitus. 
 Fruits  as  tonic,  lactogogue,  cooling,  astringent  and  in  hepatic 
obstruction.
Phytoconstituents
 The  presence  of  phenanthroindolizidine  alkaloids,  n-alkanes, 
coumarins,  triterpenoids,  flavonoids,  oxyterpene,  tannins,  and 
saponins was documented.
 The  leaves  are  reported  to  contain  O-methyltylophorinidine39, 
oleanolic  acid,  hispidin,  bergapten,  psoralene,  β-amyrin,  and  β-
sitosterol40.
 The bark was reported to contain lupeol acetate, 10-ketotetracosyl 
arachidate41, β-amyrin and triacontanol acetate42. 
LITERATURE REVIEW
Cyclophosphamide
Santos et  al.43 reported  the  first  human  fatality  of  cyclophosphamide  (CP) 
cardiotoxicity  as  a  complication  of  bone  marrow  transplantation.  High-dose 
cyclophosphamide  was  introduced  as  a  mainstay  of  numerous  preparative 
regimens for haemopoietic stem-cell  transplantation and its potential  to cause 
myocardial damage was soon recognized. 
De  Souza  et  al.44 demonstrated  that  high-dose  cyclophosphamide  (HDCY) 
therapy  could  cause  multiple  organ  toxicities  including  cardiac,  hepatic  and 
pulmonary damage. Clinical trials performed by their team infer that pretreatment 
with  antioxidants  like  amifostine  might  confer  protection  against  high-dose 
cyclophosphamide therapy could cause multiple organ toxicities. With amifostine, 
side  effects  were  mild  and  easily  controlled.  They  concluded  that  amifostine 
protection should be useful in HDCY to protect normal tissues, with acceptable 
side effects.
Gharib and  Burnett45 stated that cardiotoxicity is a potential side effect of few 
chemotherapeutic agents. The anthracycline class of cytotoxic antibiotics is the 
most  famous,  but  other  chemotherapeutic  agents  can  also  cause  serious 
cardiotoxicity  and  are  not  so  well  recognised.  Examples  include 
cyclophosphamide,  ifosfamide,  mitomycin  and  fluorouracil.  High  therapeutic 
doses of cyclophosphamide could cause a lethal cardiotoxicity that presents a 
combination of symptoms and signs of myo-pericarditis which could lead to fatal 
complications such as congestive heart failure (CHF), arrhythmias and cardiac 
tamponade. 
Lindley  et al.46 proposed that  CP itself  is a prodrug and it  is bioactivated by 
hepatic  cytochrome  P450  enzymes  via the  predominant  pathway,  4-
hydroxylation, resulting in the formation of 4-hydroxycyclophosphamide (HCY), 
the  major  active  circulating  metabolite  that  is  converted  intracellularly  to  its 
tautomer aldophosphamide which is further metabolised to the DNA cross-linking 
agent phosphoramide mustard (PM) and a toxic-byproduct, acrolein. 
Yousefipour et al.47 identified that acrolein, an environmental pollutant and a lipid peroxidation 
product is implicated in vascular pathogenesis. This study investigated the effects of acrolein on 
vascular  function  to  understand  the  underlying  mechanism  of  acrolein-induced  vascular 
responses. Urine and blood samples were collected. Changes in systolic blood pressure (SBP) 
and responses to acetylcholine and phenylephrine were determined. Acrolein (4 mg/kg, 7 days) 
significantly  increased SBP by 25%, phenylephrine vasoconstriction by 2-fold,  but  decreased 
urinary  excretion  of  nitrite  by  25%.  Acrolein  inhibited  generation  of  cyclic  guanosine  3'5'-
monophosphate (cGMP) by 98%, and did not alter expression of nitric oxide synthase (eNOS).  
Acrolein increased the generation of lipid hydroperoxide in plasma and aortic tissue by 21% and 
124% respectively, increased glutathione-S-transferase (GST) and glutathione peroxidase (GSH-
Px) activities. Acrolein up-regulated the expression of GST by 2 fold. These data suggest that 
induced SBP and altered vasoconstriction/vasodilatation in acrolein treated rats may be due to 
reduced availability of NO via increased free radical generation and reduced antioxidant defense.
Lee  et  al.48 postulated  that  “oxidative  stress” might  play  a  pivotal  role  in 
cyclophosphamide-induced cardiotoxicity. Lee and his colleagues also suggested 
that  acute  decompensating  cardiomyopathy  induced  by  cyclophosphamide  is 
usually  irreversible.  To  investigate  the  clinical  course  and  the  outcome  of 
therapy, 13 patients (1.7%) with grade III acute cardiomyopathy and hypotension 
who were treated with ablative transplant regimens between January 1980 and 
September 1995 were  analyzed by their  team. Eight  of  nine patients died of  
acute fatal  restrictive cardiomyopathy with  unresponsive hypotension (ARCH), 
whereas three of four patients who survived the initial episode died of subacute 
congestive  heart  failure  (SCHF).  Acute  fatal  restrictive  cardiomyopathy  was 
characterized with extreme sensitivity to volume overload, myocardial edema and 
a  rapidly  fatal  course.  It  was  associated  with  progressive,  unresponsive 
hypotension, reduced left  ventricular stroke work index and markedly reduced 
systemic and pulmonary vascular resistance indices. Of 10 patients who received 
conventional therapy, nine died and one sustained chronic CHF. One of three 
patients  with  ARCH on  antioxidant  therapy of  ascorbic  acid  and  theophylline 
survived the episode. The data suggests peripheral vascular collapse may also 
be responsible for fatal ARCH.  
Sies6 defined  “oxidative  stress”  as  an  imbalance  between  oxidants  and 
antioxidants in favour of the oxidants, potentially leading to damage. Oxidants 
are formed as a normal product of aerobic metabolism but can be produced at 
elevated rates under pathophysiological conditions. Antioxidant defense involves 
several  strategies,  both  enzymatic  and  non-enzymatic.  In  the  lipid  phase, 
tocopherols  and carotenes as well  as oxy-carotenoids are of'  interest,  as are 
vitamin A and ubiquinols. In the aqueous phase, there are ascorbate, glutathione 
and other compounds. In addition to the cytosol, the nuclear and mitochondrial 
matrices and extracellular fluids are protected. Overall, these low molecular mass 
antioxidant molecules add significantly to the defense provided by the enzymes 
superoxide dismutase, catalase and glutathione peroxidases.
Ficus hispida
Mandal  et al.49 evaluated the methanol extract of the leaves of  Ficus hispida 
Linn.  (Moraceae)  for  hepatoprotective  activity  in  rats  by  inducing  acute  liver 
damage by paracetamol (750 mg/kg, p.o.). The extract at an oral dose of 400 
mg/kg exhibited a significant protective effect by lowering the serum levels of 
transaminase  (SGOT  and  SGPT),  bilirubin  and  alkaline  phosphatase  (ALP). 
These  biochemical  observations  were  supplemented  by  histopathological 
examination of liver sections. The activity of extract was also comparable to that 
of Liv-52 a known hepatoprotective formulation.
Khan et al.40 isolated oleanolic acid from the leaves of Ficus hispida and he had 
cited that Ficus hispida leaves contain bergapten, β-amyrin and β-sitosterol.
Huong and Trang50 extracted six alkaloids in the total alkaloid residue from the 
leaves  of  Ficus  hispida L.  One  of  them  was  elucidated  as  hispidin  by 
spectrocopic method which has demonstrated cytotoxicity toward human hepatic 
cancer cell line Hep-2 and human heart cancer line RD. 
 
Senthil  et al.51 investigated the protective effect of oleanolic acid (OA) against 
isoproterenol-induced myocardial ischemia in rat myocardium. Wistar strain rats 
were  pretreated  with  OA  (20,  40,  and  60  mg/kg,  s.c)  for  7  days  and  then 
intoxicated with isoproterenol (ISO, 85 mg/kg, sc for 2 consecutive days). Heart 
were excised from the experimental animals and assessed for the activities of 
marker enzymes, the levels of lipid peroxide products [thiobarbituric acid reactive 
substances (TBARS), lipid hydroperoxides (HP) and conjugated dienes (CD)], 
myeloperoxidase (MPO), lipid profiles, and membrane-bound ATPase enzymes. 
Troponin  T  and  I  were  estimated  in  plasma.  Leakage  of  cardiac  markers, 
elevated lipid peroxidation with increased lipid profiles and decreased activities of 
membrane-bound  ATPase  enzymes  were  confirmed  the  severe  myocardial 
damage  occurring  as  a  consequence  of  isoproterenol-induced  ischemia,  and 
they  also  showed  the  significant  improvement  effected  by  oleanolic  acid 
pretreatment. These findings provided evidence that oleanolic acid was found to 
be protecting rat myocardium against ischemic insult and the protective effect 
could  attribute  to  its  anti-oxidative,  anti-hyperlipedemic,  and  anti-arrhythmic 
properties as well as its membrane-stabilizing action.
Park  et al.52 in the course of  screening for reactive oxygen species scavengers from natural 
products, isolated an antioxidant from the mycelial culture broth of Phellinus linteus and identified 
as  hispidin.  The hispidin  content  was  reached its  maximum level  at  12  days  after  onset  of  
inoculation. About 2.5 mg/mL of hispidin was produced by P. linteus in a yeast-malt medium.  
Hispidin  inhibited  22.6  and  56.8% of  the  super  oxide  anion  radical,  79.4  and  95.3% of  the 
hydroxyl radical, and 28.1 and 85.5% of the DPPH radical at 0.1 and 1.0 mM, respectively. The 
positive  control  alpha-tocopherol  scavenged 25.6 and 60.3%, 74.6 and 96.3%, and 32.7 and 
77.5% of each radical, respectively, at the same concentrations. 
Peraza-Sánchez39 isolated  a  new  norisoprenoid,  ficustriol  (1),  and  the  known 
phenanthroindolizidine alkaloid O-methyltylophorinidine (2), from a CHCl3 extract of the leaves 
and twigs of Ficus hispida. O-Methyltylophorinidine showed potent cytotoxic activity when tested 
against a small panel of human cancer cells, while ficustriol was inactive. 
Yang  et  al.53 examined  the  molecular  mechanisms  for  the  anti-inflammatory 
activity of phenanthroindolizidine alkaloids were in an in vitro system mimicking 
acute  inflammation  by  studying  the  suppression  of  lipopolysaccharide 
(LPS)/interferon-gamma  (IFNgamma)-induced  nitric  oxide  production  in 
RAW264.7  cells.  Two  of  the  phenanthroindolizidine  alkaloids,  NSTP0G01 
(tylophorine)  and  NSTP0G07  (ficuseptine-A),  exhibited  potent  suppression  of 
nitric  oxide  production  and  did  not  show  significant  cytotoxicity  to  the 
LPS/IFNgamma-stimulated  RAW264.7  cells,  in  contrast  to  their  respective 
cytotoxic effects on cancer cells. Tylophorine was studied further to investigate 
the responsible mechanisms and  it was found that NSTP0G01 exerts its anti-
inflammatory effects by inhibiting expression of the proinflammatory factors and 
related signaling pathways.
Liu54 reviewed the pharmacology of oleanolic acid and cited that oleanolic acid 
has protective effect against cyclophosphamide-induced toxicities.
OBJECTIVE AND SCOPE OF RESEARCH
The most imperative obstacle in cancer chemotherapy is the non-specific 
cytotoxic  action  on  both  the  tumor  cells  and  normal  healthy  cells.55 
Cyclophosphamide (CP), an oxazophosphorine-alkylating agent,  is  extensively 
used  as  an  antineoplastic  and  immunosuppressant  drug.  Despite  its  wide 
spectrum of clinical uses, CP is known to cause multiple organ toxicity. 44 High 
therapeutic doses of cyclophosphamide could cause a lethal cardiotoxicity that 
presents a combination of symptoms and signs of myo-pericarditis which could 
lead to fatal complications such as congestive heart failure (CHF), arrhythmias 
and cardiac tamponade.45  
The  prime  factor  for  therapeutic  and  toxic  effects  of 
cyclophosphamide  is  the  requirement  of  bioactivation  by  hepatic  microsomal 
cytochrome P450 mixed functional oxidase system, to phosphoramide mustard 
and acrolein, which are the active cytotoxic metabolites.46,56 Bioconversion of CP 
to  these metabolites leads to  the formation of  high levels  of  reactive  oxygen 
species  (ROS),  which  culminate  in  oxidative  stress.57 An  ample  literature 
implicate that oxidative stress plays a key role in the pathogenesis of CP induced 
cardiotoxicity.5,48 
Cytoprotectants  like  amifostine,  mesna and dexrazoxane  were  used to 
manage  the  toxic  effects  of  cancer  chemotherapy,  but  these  agents  are  not 
approved for wide clinical use due to lack of efficacy, gastrointestinal side effects,  
hypotension,  hypersensitivity  reactions,  anxiety,  urinary  retention  and 
myelosuppression.58-60 Limitations to such conventional treatment have spurred 
the development of new treatment modalities.
Plants are arguably poised for a comeback as sources of human health 
products,  mainly  due  to  their  enormous  propensity  to  synthesize  complex 
mixtures  of  structurally  diverse  compounds,  which  could  provide  a  safer  and 
more holistic approach to disease treatment and prevention.27 Plant extracts and 
natural compounds have also shown protective effect on CP-induced toxicity.61-65 
The genus Ficus constitutes an important group of trees, not only of their 
immense  medicinal  value  but  also  of  their  growth  habits  and  religious 
significance. The genus  Ficus  is an exceptionally large pantropical genus with 
over 700 species and belongs to the family Moraceae. Almost all parts of this 
plant  are used as a folklore remedy for  the treatment of  various ailments by 
Indian traditional healers but the leaves are of particular interest from a medicinal 
point  of  view,  as  an  anti-diarrhoeal,38 hepatoprotective,49 anti-inflammatory,66 
antitussive,  antipyretic,  astringent,  vulnerary,  haemostatic  and anti-ulcer  drug, 
among other parts.67,68
Ficus hispida leaves have been reported to contain hispidin, oleanolic 
acid, bergapten, psoralen, β-amyrin and β-sitosterol40,50 and the bark comprises 
lupeol acetate, β-sitosterol and β-amyrin acetate.41,69 An ample literature suggests 
that  these  compounds  exhibit  significant  antioxidant  and/or  cardioprotective 
properties.70-74
In  this  light,  I  hypothesized  that  F. hispida  could  be  evaluated  for  its 
cardioprotective effect. The claim that the cardioprotective activity of  F. hispida 
resides in  the  leaves  is  speculative  and  has  not  yet  been documented.  The 
present  study was  designed to  investigate  the  cardioprotective  activity  of  the 
methanolic leaf extract of Ficus hispida on cyclophosphamide induced oxidative 
cardiac injury in rats.
DESIGN OF WORK
CHAPTER 1: Collection and processing of plant
 Collection and authentication of plant
 Drying and pulverization 
 Preparation of extract
CHAPTER 2: Phytochemical investigation
 Preliminary phytochemical screening
CHAPTER 3: In vivo animal studies
 Purchase of drugs and chemicals
 Procurement of animals
 Treatment regimen
 Biochemical investigation
• Assay of enzymatic indices
• Assay of tissue antioxidants
• Assay of lipid peroxidation
• Assay of protein content
• Assay of TNF-α
• Assay of nitric oxide.
 Histopathological investigation
 Statistical analysis.
EXPERIMENTAL PROTOCOLS
CHAPTER 1: COLLECTION AND PROCESSING OF PLANT
I. Collection and authentication of plant
The leaves of  Ficus hispida Linn. (Moraceae) were collected during the 
month of February 2007 from the herbal garden of Anna Siddha Hospital and 
Research  Centre,  Chennai,  India.  A  voucher  specimen (PARC/2007/Vel’s/28) 
was deposited in the Plant Anatomy Research Centre, Pharmacognosy Institute, 
Chennai, India and was authenticated by Dr.Jayaraman.
II. Drying and pulverization 
The  leaves  were  dried  under  shade  and  pulverized  in  a  mechanical 
grinder and stored in a closed container for further use.
III. Preparation of extract
The powdered leaves were defatted with petroleum ether (B.P. 60–80°C) 
and  then  extracted  with  methanol  in  a  Soxhlet  extractor.  On  evaporation  of 
methanol from the methanol extract  in vacuo, a greenish coloured residue was 
obtained (yield  4.7% (w/w)  with  respect to the dry starting material)  and was 
stored in a desiccator and used for further studies. 
CHAPTER 2: PHYTOCHEMICAL INVESTIGATION
The  extract  obtained  from  the  powdered  leaves  of  Ficus  hispida was 
subjected to qualitative tests for the identification of various phytoconstituents75-78. 
I. Test for alkaloids
1. Mayer’s test: To the 1ml of extract, 1 ml of Mayer’s reagent (Potassium 
mercuric iodide solution) was added. Appearance of yellowish-whitish 
precipitate indicates the presence of alkaloids.
2. Dragendorff’s test: To the 1ml of extract, 1 ml of Dragendorff’s reagent 
(potassium  bismuth  iodide  solution)  was  added.  An  orange-red 
precipitate indicates the presence of alkaloids.
3. Hager’s  test:  To  1  ml  extract,  3ml  of  Hager’s  reagent  (saturated 
aqueous solution of picric acid) was added; yellow coloured precipitate 
indicates the presence of alkaloids.
4. Wagner’s test: To the 1 ml of extract 2 ml of Wagner’s       reagent 
(iodine  in  potassium iodide)  was  added,  formation  of  reddish  brown 
precipitate indicates the presence of alkaloids.
II. Test for triterpenoids
1. Noller’s test:  Two or three granules of tin metal were added to 2 ml 
thionyl chloride solution. Then 1ml of the extract was added into test 
tube and warmed, the formation of pink colour indicates the presence of 
triterpenoids.
III. Test for flavonoids
1. Shinoda’s Test:  The alcoholic extract was treated with magnesium foil 
and concentrated HCl. Appearance of orange red colour indicates the 
presence of flavonols.
2. The drug in alcoholic and aqueous solution with few ml of ammonia was 
seen under U.V. and visible light; formation of fluorescence indicates 
the presence of flavonoids.
3. Little quantity of extract was treated with amyl alcohol, sodium acetate 
and  ferric  chloride.  A  yellow  colour  solution  formed,  disappears  on 
addition of an acid indicates the presence of flavonoids.
4. The extract  was  treated  with  sodium hydroxide;  formation  of  yellow 
colour indicates the presence of flavones.
5. The extract was treated with concentrated H2SO4, formation of yellow or 
orange colour indicates the presence of flavones.
6. The  alcoholic  and  aqueous  extract  was  treated  with  10%  sodium 
chloride;  formation  of  yellow  colour  indicates  the  presence  of 
coumarins.
IV. Test for steroids 
1. Liebermann-Burchard test: The extract was dissolved in a few drops 
of chloroform, 10 drops of acetic anhydride, 3ml of glacial acetic acid 
were  added,  warmed  and  cooled  under  the  tap  and  drops  of 
concentrated  sulphuric  acid  were  added along  the  sides  of  the  test 
tube.  Appearance  of  bluish-green  colour  indicates  the  presence  of 
sterols.
2. Salkowski  test:  The extract  was  dissolve  in  chloroform and equal 
volume of conc. H2SO4 was added.  Formation of bluish-red to cherry 
colour  in  chloroform layer  and  green  fluorescence  in  the  acid  layer 
represents the steroidal components in the tested extract.
V. Test for tannins and phenolics 
1. Lead acetate test:  To the filtrate,  basic lead acetate solution (10%) 
was added.  Formation of  white  precipitate indicates the presence of 
tannins.
2. Ferric  chloride  test:  To  1ml  of  filtrate,  ferric  chloride  solution  was 
added, formation of a deep blue or greenish black colour shows the 
presence of tannins.
3. The filtrate  was  treated  with  potassium ferric  cyanide  and ammonia 
solution. A deep red colour indicates the presence of tannins.
4. To the test extract, strong potassium dichromate solution was added. A 
yellow  colour  precipitate  indicates  the  presence  of  tannins  and 
phenolics.
VI. Test for Saponins: 
1 ml of the extract was diluted separately with distilled water to 20 ml and 
was shaken in a graduated cylinder for 15 minutes lengthwise. A one cm layer of 
foam indicates the presence of saponins. 
VII. Test for carbohydrates 
1. Molisch’s test:  To 2ml of the extract, 1 ml of  α-napthol solution was 
added; concentrated sulphuric acid was added through the side of the 
test  tube.  Purple  or  reddish  violet  colour  at  the  junction  of  the  two 
liquids reveals the presence of carbohydrates.
2. Fehling’s test:  To 1ml of the extract, add equal quantities of Fehling’s 
solution  A  and  B,  upon  heating  formation  of  a  brick  red  precipitate 
indicates the presence of sugars.
3. Benedict’s test:  To 5 ml of  Benedict’s reagent, add 1ml of  extract 
solution and boil for 2 minutes and cool. Formation of red precipitate 
shows the presence of sugars.
VIII. Test for proteins and amino acids
1. Biuret test:  2 drops of 1% CuSO4 solution was added to 1 ml of 40% 
sodium hydroxide solution till the appearance of blue colour, and then 1 
ml of the extract was also added. Formation of pinkish or purple violet 
colour indicates the presence of proteins.
2. Ninhydrin test:  Two drops of freshly prepared 0.2% ninhydrin reagent 
(0.1% solution in n-butanol) were added to small quantity of the extract 
solution and heated. Development of blue colour reveals the presence 
of proteins, peptides or amino acids.
3. Xanthoprotein test: To 1ml of the extract, 1ml of concentrated nitric 
acid was added. A white precipitate appeared, it was boiled and cooled. 
Then 20% of sodium hydroxide or ammonia was added. Orange colour 
indicates the presence of aromatic amino acids.
4. Millon’s test:  1ml of test solution was acidifed with sulphuric acid and 
Millon’s  reagent  was  added  and  this  solution  was  boiled.  A  yellow 
precipitate was formed which indicates the presence of proteins.
CHAPTER 3: IN VIVO ANIMAL STUDIES
I. Purchase of drugs and chemicals
Cyclophosphamide  (Ledoxan®)  was  purchased  from  Dabur  Pharma 
Limited, New Delhi,  India.  All  other chemicals and solvents used were of the 
highest purity and analytical grade.
II. Procurement of animals
The study was conducted on male Wistar rats (150±10 g). Animals were 
obtained from the Animal House, Vel’s College of Pharmacy, The Tamilnadu Dr. 
M.G.R. Medical University, Chennai, India. Animals were fed with commercially 
available  standard  rat  pelleted  feed  (M/s  Pranav  Agro  Industries  Ltd.,  India) 
under the trade name Amrut rat/mice feed and water was provided  ad libitum. 
The animals were deprived of food for 24 h before experimentation but allowed 
free access to tap water. The rats were housed under conditions of controlled 
temperature  (25±2 ◦C) and were  acclimatized to  12-h  light:  12-h  dark  cycles. 
Experimental  animals were used after obtaining prior permission and handled 
according  to  the  University  and  institutional  legislation  as  regulated  by  the 
Committee  for  the  Purpose  of  Control  and  Supervision  of  Experiments  on 
Animals (CPCSEA), Ministry of Social Justice and Empowerment, Government of 
India.
III. Treatment regimen
The experimental animals were randomized into four groups of six rats 
each as follows:
Group I   : Control rats received normal saline (1 mL/kg body weight),  
                 orally for 10 days.                 
Group II : Rats were injected intraperitoneally with a single dose of CP 
                 (200 mg/kg body weight) dissolved in saline, on the first day  
                 of the experimental period.        
Group III: Rats received FH extract by oral gavage (400 mg/kg body  
                weight for 10 days). 
Group IV: Rats were administered CP as in Group II, immediately 
                followed by supplementation with FH extract (400 mg/kg body  
                weight) by oral gavage for 10 consecutive days.
                After the 10 days experimental period (i.e., on the 11 th day), all the 
animals  were  anesthetized  and  decapitated.  Heart  tissues  were  immediately 
excised  and  rinsed  in  ice  cold  physiological  saline.  The  tissues  were 
homogenized in 0.01 M Tris-HCl buffer (pH 7.4) and aliquots of this homogenate 
were used for the assays.  Blood was collected and serum was separated for 
analysis of biochemical parameters.
IV. BIOCHEMICAL INVESTIGATION 
A. Assay of enzymatic indices
1. Creatine phosphokinase (CPK, creatine kinase, E.C. 2.7.3.2)
This enzyme catalyzes the reaction:
The enzyme activity was assayed by the method of Okinaka et al.79 
Reagents
1. Substrate: Creatine solution
2. ATP solution
3. Cysteine hydrochloride solution
4. 10% Trichloro-acetic acid
5. Ammonium molybdate solution
6. 1-amino-2-naphthol-6-sulphonic acid (ANSA).
Creatine + ATP → Creatine phosphate + ADP
Procedure
The reaction mixture comprised of 0.1 ml of plasma/tissue homogenate, 
0.1 ml of substrate, 0.1 ml of ATP solution and 0.1 ml of cysteine-hydrochloride 
solution.  The  final  volume  was  made  up  to  2.0  ml  with  distilled  water  and 
incubated at 37.8OC for 30 min. The reaction was arrested by the addition of 1.0 
ml  of  10%  TCA  (trichloroacetic  acid)  and  the  contents  were  subjected  to 
centrifugation. To 0.1 ml of the supernatant, 4.3 ml distilled water and 1.0 ml 
ammonium molybdate were added and incubated at room temperature for 10 
minutes. 0.4 ml of ANSA was added and the colour developed was read at 640 
nm  after  20  min.  The  activity  of  the  enzyme  was  expressed  as  μmoles  of 
phosphorus liberated/min/mg protein.
2. Lactate dehydrogenase (LDH, E.C. 1.1.1.27)
This enzyme catalyzes the reaction:
The enzyme activity was assayed by the method of King.80
Reagents
1. 0.1 M glycine buffer: 7.5 g of glycine and 5.85 mg of sodium 
chloride were dissolved in 1 litre of distilled water; pH 10. 
2. Substrate: 2.76 g of lithium lactate was dissolved in glycine buffer in  
situ and the volume was made up to 100 ml.
3. 0.4 N sodium hydroxide.
4. NAD+ solution.
5. 2,4-dinitro phenyl  hydrazine (DNPH): 0.2% in 1 N HCl, prepared by 
dissolving 200 mg of DNPH in 1 litre of 1 N HCl.
6. Standard pyruvate solution: 11 mg of sodium pyruvate was dissolved 
in 100 ml of phosphate buffer. This contained 1 µmole of pyruvate/ml.
Lactate + NAD+ → Pyruvate + NADH
Procedure
About  1.0  ml  of  the  buffered  substrate,  0.1  ml  of  plasma/tissue 
homogenate was added and the tubes were incubated at 37.8ºC for 15 min. After 
adding 0.2 ml of NAD+ solution, the incubation was continued for another 15 min. 
The  reaction  was  arrested  by  adding  0.1  ml  of  DNPH  (2,  4-dinitrophenyl 
hydrazine), and the tubes were incubated for a further period of 15 min at 37.8°C 
after  which  7.0  ml  of  0.4N NaOH was  added and the colour  developed was 
measured at 420 nm. Suitable aliquots of the standards were also analyzed by 
the same procedure. The activity of the enzyme was expressed as  μmoles of 
pyruvate liberated/min/mg protein.
3.  Aspartate  aminotransferase  (AST,  glutamic-oxaloacetic  transaminase, 
E.C. 2.6.1.1)
This enzyme catalyzes the reaction:
The enzyme activity was assayed by the method of King.81
Reagents
1. Substrate: 1.33 g of L-aspartic acid and 15 mg of 2-oxo glutaric acid 
were dissolved in 20.5 ml of buffer and 1 N sodium hydroxide to adjust 
the pH to 7.4 and made up to 100 ml with the phosphate buffer.
2. Sodium hydroxide: (0.1 N).
3. 2,4-dinitro phenyl hydrazine (DNPH): 0.2% in 1 N HCl.
4. Standard pyruvate solution: 11 mg of sodium pyruvate was dissolved 
in 100 ml of phosphate buffer. This contained 1 µmole of pyruvate/ml.
L-aspartate + 2-oxoglutarate → oxaloacetate + L-gluatamate
Procedure
1 ml of buffered substrate was incubated at 37°C for 10 minutes. Then 0.2 
ml of plasma/tissue homogenate was added in the test tubes and incubated at 
37°C for 1 hour. The reaction was arrested by adding 1.0 ml of DNPH reagent 
and tubes were kept at room temperature for 20 minutes. Then 10 ml of 0.4N 
sodium hydroxide solution was added. A set of pyruvic acid was also treated in a 
similar  manner  for  the  standard.  The  colour  developed was  read  at  520  nm 
against the reagent blank. The activity of the enzyme was expressed as μmoles 
of pyruvate liberated/min/mg protein.
4.  Alanine  aminotransferase  (ALT,  glutamic-pyruvic  transaminase,  E.C. 
2.6.1.2)
This enzyme catalyzes the reaction:
The enzyme activity was assayed by the method of King.81
 
Reagents
1. Phosphate buffer: 0.1 M; pH 7.4.
2. Substrate: 1.78 g of DL-alanine and 30 mg of  2-oxo glutaric acid were 
dissolved in 20 ml of buffer. About 0.5 ml of 1 N sodium hydroxide was 
added and made up to 100 ml with buffer.
3. Sodium hydroxide: (0.1 N).
4. 2,4-dinitro phenyl hydrazine (DNPH): 0.2% in 1 N HCl.
5. Standard pyruvate solution: 11 mg of sodium pyruvate was dissolved in 
100 ml of phosphate buffer. This contained 1 µmole of pyruvate/ml.
L-alanine + 2-oxoglutarate → Pyruvate + L-gluatamate
Procedure
1 ml of buffered substrate was incubated at 37°C for 10 minutes. Then 0.2 
ml of plasma/tissue homogenate was added in the test tubes and incubated at 
37°C for  30  minutes.  The  reaction  was  arrested  by  adding  1.0  ml  of  DNPH 
reagent and tubes were kept at room temperature for 20 minutes. Then 10 ml of 
0.4N  sodium hydroxide  solution  was  added.  A  set  of  pyruvic  acid  was  also 
treated in a similar manner for the standard. The colour developed was read at 
520 nm against the reagent blank. The activity of the enzyme was expressed as 
μmoles of pyruvate liberated/min/mg protein.
B. Assay of Tissue Antioxidants
1. Superoxide dismutase (SOD, E.C. 1.15.1.1)
This  enzyme  catalyzes  the  dismutation  of  superoxide  anion  (O2-.)  to 
hydrogen peroxide and molecular oxygen in the following manner:
The enzyme activity was assayed by the method of Misra and Fridovich.82
Reagents
1. Carbonate-bicarbonate buffer: 0.1 M; pH 10.2.
2. EDTA solution: 0.6 mM.
3. Epinephrine: 1.8 mM (prepared in situ).
4. Absolute ethanol.
5. Chloroform.
H20 + 2O2-. + 2H+ → 2H2O2 + O2
Procedure
0.1 ml of tissue homogenate was added to the tubes containing 0.75 ml 
ethanol  and 0.15 ml chloroform (chilled in ice) and centrifuged.  To 0.5 ml of  
supernatant,  added  0.5  ml  of  0.6  mM  EDTA  solution  and  1  ml  of  0.1  M 
carbonate-bicarbonate (pH 10.2) buffer. The reaction was initiated by the addition 
of  0.5  ml  of  1.8  mM  epinephrine  (freshly  prepared)  and  the  increase  in 
absorbance at 480 nm was measured. One unit  of  the SOD activity was the 
amount of protein required to give 50% inhibition of epinephrine autoxidation.
2. Catalase (CAT, E.C. 1.11.1.6)
This enzyme catalyzes conversion of hydrogen peroxide into water and 
molecular oxygen.
 
The enzyme activity was assayed by the method of Sinha.83
Reagents
1. Dichromate-acetic acid reagent: 5% potassium dichromate in   
              water was mixed with glacial acetic acid in the ratio of 1:3 (v/v). 
2. Phosphate buffer: 0.01 M; pH 7.0.
3. Hydrogen peroxide: 0.2M.
Procedure
0.1  ml  of  the  tissue  homogenate  was  added  to  the  reaction  mixture 
containing 1ml of 0.01 M phosphate buffer (pH 7.0) pre-warmed to 37°C, 0.4 ml  
of  distilled  water  and  the  mixture  was  incubated  at  37°C.  The  reaction  was 
initiated by the addition of 0.5 ml of 0.2 M hydrogen peroxide and the reaction 
mixture was incubated at 37°C for one minute. The reaction was terminated by 
the addition of 2 ml of dichromate-acetic acid reagent after  15, 30, 45, and 60 
seconds. Standard hydrogen peroxide in the range of 4-20  µmoles were taken 
2H2O2 → 2H2O + O2
and treated in the same manner. All the tubes were heated in a boiling water  
bath for 10 minutes, cooled and and the green colour that developed was read at 
590 nm against blank containing all components except the enzyme. Catalase 
activity was expressed in terms of µmoles of H2O2 consumed/min/mg protein. 
 3. Glutathione peroxidase (GPx, E.C. 1.11.1.9)
This  enzyme  catalyzes  the  reduction  of  H2O2 using  glutathione  as 
substrate.
   
 
The enzyme activity was assayed by the method of Rotruck et al.84
Reagents
1. Sodium phosphate buffer: 0.32 M; pH 7.0.
2. Ethylene diamine tetra-acetate (EDTA): 0.8 mM.
3. Sodium azide: 10 mM.
4. Reduced glutathione: 4mM.
5. Hydrogen peroxide: 2.5 mM.
6. Trichloro acetic acid (TCA): 10%
7. Disodium hydrogen phosphate: 0.3M.
8. 5,5'-dithiobis (2-nitro benzoic acid) (DTNB): 0.04%; 40 mg of DTNB in 
1% sodium citrate.
9. Standard reduced glutathione: 10 mM.
Procedure
The assay mixture containing 0.5 ml sodium phosphate buffer, 0.1 ml of 
10mM  sodium  azide,  0.2  ml  of  4  mM  reduced  glutathione,  0.1  ml  of  2.5  
mMH2O2, and 0.5 ml of 1:10 cell extract was taken and the total volume was 
made up to 2.0 ml with distilled water. The tubes were incubated at 37 8C for 3 
min  and  the  reaction  was  terminated  by  the  addition  of  0.5  ml  of  10% 
trichloroacetic  acid  (TCA).  To determine the  residual  glutathione  content,  the 
supernatant  was  removed  after  centrifugation,  and  to  this  4.0  ml  disodium 
2GSH + H2O2 → GSSG + 2H2O
hydrogen  phosphate  (0.3  M)  solution  and  1  ml  dithio-bis-nitrobenzoic  acid 
(DTNB) reagent were added. The colour that developed was read at 412 nm 
against a reagent blank containing only phosphate solution and DTNB reagent in 
a  spectrophotometer.  Suitable  aliquots  of  the  standard  were  also  treated 
similarly. The enzyme activity is expressed in terms of µg of GSH utilized/min/mg 
protein.
 
4. Glutathione-S-transferase (GST, E.C. 2.5.1.18)
This  detoxifying  enzyme  catalyzes  the  conjugation  of  xenobiotics/ 
electrophiles  (E)  with  the  reduced  glutathione  (GSH),  which  acts  as  an 
electrophile.
   
 
The enzyme activity was assayed by the method of Habig et al.85
Reagents
1. Phosphate buffer: 0.3 M; pH 6.5.
2. 1-chloro-2, 4-dinitrobenzene (CDNB) in 95% ethanol:  30 mM.
3. Reduced glutathione: 30 mM.
4. Double distilled water.
Procedure 
The reaction mixture contained 1.0 ml of 0.3 M phosphate buffer, 0.1 ml of  
30 mM 1-chloro-2, 4-dinitrobenzene (CDNB) in 95% ethanol and 1.7 ml of double 
distilled water. After pre-incubating the reaction mixture at 37°C for 5 min, the 
reaction was started by the addition of 0.1 ml of tissue homogenate and 0.1 ml of 
30  mM glutathione as  substrate.  Then,  the  total  reaction  mixture  (3  ml)  was 
mixed well and the absorbance was read at 340 nm for 3 min at an interval of 30 
sec.  Reaction mixture without the enzyme was used as blank. The activity of 
GST is expressed as μmoles of GSH-CDNB conjugate formed/min/mg protein.
E + GSH → EH + GSSG
5. Glutathione reductase (GR, E.C. 1.6.4.2)
This enzyme catalyzes the conversion of oxidized glutathione (GSSG) to 
reduced glutathione (GSH) by the oxidation of NADH to NAD+.
The enzyme activity was assayed by the method of Staal et al.86 
Reagents
1. Sodium phosphate buffer: pH 7.4.
2. EDTA: 25 mM.
3. Oxidized glutathione (GSSG): 12.5 mM.
4. NADPH: 3 mM.
Procedure
To the assay mixture containing 0.2 ml tissue homogenate, 1.5 ml sodium 
phosphate  buffer,  0.5  ml  of  25  mM  EDTA,  0.2  ml  of  12.5  mM  oxidized 
glutathione, and 0.1 ml of 3 mM NADPH were added and immediately read at 
340 nm against blank containing all the components except the enzyme for 3 min 
at  30  sec.  interval.  The  activity  of  GR  is  expressed  as  µmoles  of  NADPH 
oxidized/min per mg protein.
6. Reduced glutathione: (GSH)
The total reduced glutathione was determined according to the method of 
Ellman.87
Reagents
1. Phosphate buffer: 0.2 M; pH 8.0.
2. DTNB [5, 5 dithiobis (2-nitrobenzoic acid)] reagent: 0.6 mM.
3. Trichloro-acetic acid (TCA): 5%.
Procedure
0.1 ml of tissue homogenate was precipitated with 5% TCA (trichloroacetic 
acid). The contents were mixed well for complete precipitation of proteins and 
centrifuged. To 0.1 ml of supernatant, 2.0 ml of 0.6 mM DTNB [5, 5 dithiobis (2-
GSSG + NADPH + H+ → 2GSH + NADP+
nitrobenzoic acid)] reagent and 0.2 M phosphate buffer (pH 8.0) were added to 
make up to a final volume of 4.0 ml. The absorbance was read at 412 nm against 
a  blank  containing  TCA (trichloroacetic  acid)  instead  of  sample.  A  series  of 
standards treated in a similar way also run to determine the glutathione content. 
The amount of glutathione was expressed as nmoles/g heart tissue. 
C. Assay of lipid peroxidation
Lipid peroxidation (LPO) was assayed by the method of Ohkawa et al.88 in 
which the malondialdehyde (MDA) released served as the index of LPO.
Reagents
1. Standard: 1, 1, 3, 3-tetra ethoxypropane (TEP). 
2. Sodium dodecyl sulphate: 8.1%
3. Acetic acid: 20%
4. Thiobarbituric acid (TBA): 0.8%
5. n-butanol: pyridine mixture (15:1 v/v).
Procedure
To 0.2 ml of tissue homogenate, 0.2 ml of 8.1% SDS, 1.5 ml of 20% acetic 
acid (pH 3.5) and 1.5 ml of 0.8% TBA were added. The mixture was made up to 
4.0 ml with water and then heated in a water bath at 95.8ºC for 60 min using 
glass ball as a condenser. After cooling, 1.0 ml of water and 5 ml of n-butanol:  
pyridine  (15:1  v/v)  mixture  were  added  and  shaken  vigorously.  After 
centrifugation  at  4000  rpm  for  10  min,  the  organic  layer  was  taken  and  its 
absorbance  was  measured  at  532  nm.  The  level  of  lipid  peroxides  was 
expressed as nmoles of MDA formed/mg of protein.
D. Assay of protein content
The protein content of heart tissue was estimated by the method of Lowry 
et al.89
Reagents
1. Solution A: 2% sodium carbonate in 0.1 N sodium hydroxide solution. 
2. Solution B: 0.5% copper sulphate in 1% sodium or potassium tartrate. 
50 ml of solution A was mixed with 1 ml of solution B in situ. 
3. Folin’s phenol reagent: Commercial sample.
4. Standard  solution:  100  mg  of  bovine  serum  albumin  (BSA)  was 
dissolved in 100 ml of distilled water with the aid of a small amount of  
alkali. This stock solution was diluted 1 in 10 (in situ) to give a working 
standard containing 100 µg/ml.
Procedure
To 0.1 ml of  tissue homogenate,  0.9 ml of  distilled water  and 5 ml of 
alkaline copper reagent were added and mixed well and allowed to stand at room 
temperature for 10 minutes. Standard solution containing bovine serum albumin 
(BSA) in the range of 10-100 µg/ml and the blank containing 1.0 ml of water were 
treated  similarly.  0.5  ml  of  Folin’s  reagent  was  added  and  the  blue  colour 
developed was read at 640 nm. 
The protein level was expressed as mg/g of tissue.
E. Assay of  tumor necrosis factor (TNF)-α
TNF-α was assayed by using the commercially available TNF-α assay kit.
E. Assay of nitric oxide (NO)
NO was assayed by using the commercially available NO assay kit.
V. HISTOPATHOLOGICAL INVESTIGATION90,91
Reagents
1. Formal saline: 10% formalin in normal saline.
2. Ethanol/isopropanol.
3. Xylene.
4. Paraffin wax.
5. Hematoxylin and eosin (H & E) stain.
6. Mordant: Potassium aluminium sulphate (Potash alum).
Procedure
Tissue biopsies from the heart were fixed in 10% formal saline, subjected 
to dehydration with increasing concentrations of ethanol and then embedded with 
paraffin wax. Following  dehydration and embedding,  histological sections were 
cut  (5-7  µm) with rotary microtome and the paraffin was washed off with three 
xylene baths,  followed by three isopropanol baths, and rehydration. Finally, the 
section  were  stained  with  hematoxylin  and  eosin  (H  &  E)  and  examined 
microscopically. 
Summary and explanation
 The  purpose  of  fixation  is  to  prevent  substantially  any 
physicochemical  alteration of the tissue and to maintain it  in the 
initial state in which it was collected. 
 The purpose of dehydration is to replace the water present in the 
tissues by a compound which is itself substituted- possibly with the 
use of solvents--by the infiltration/embedding compound. 
 The purpose of the infiltration/embedding is to solidify the tissue to 
make  it  possible  to  make  the  slices  as  thin  as  possible,  thus 
enabling a more extensive examination. 
 Rehydration restores the tissue more or less to its initial condition, 
permitting the desired analysis.
 Hematoxylin (a natural dye), stains the nuclei with blue/black, whilst 
eosin (a xanthene dye)  stains the cytoplasm and the connective 
tissue with varying shades of pink. 
 The addition of a mordant to an appropriate dye solution results in a 
very sudden, dramatic change in colour, which occurs due to the 
chelation  between  the  mordant  (potash  alum)  and  the  dye 
(hematoxylin).
Principle
Hematoxylin,  a  basic  bye  is  oxidized  to  hematein  with  a  mordant,  a 
metallic ion such as the salts of aluminium. The positively charged aluminium-
hematein complex combines with the negatively charged phosphate groups of 
the  nucleic  acids  (DNA  and  RNA)  forming  blue/purple  colour,  which  is 
characteristic of hematoxylin stains. Eosin is an acidic dye, which is considered 
to have a selective affinity for the basic parts of the cell, i.e., the cytoplasm. Thus, 
the  hematoxylin  and  eosin  (H  &  E)  stain  is  used  to  demonstrate  different 
structures of the tissue.
VI. STATISTICAL ANALYSIS
The results were expressed as mean ± standard deviation (S.D.) for six 
animals in each group. Differences between groups were assessed by one-way 
analysis  of  variance  (ANOVA)  using  the  SPSS  13.0  software  package  for 
Windows. Post hoc testing was performed for inter-group comparisons using the 
least  significance  difference  (LSD)  test.  P <  0.05  has  been  considered  as 
statistically significant.
RESULTS
Effect of Ficus hispida on the levels of diagnostic marker enzymes
In the present study, intraperitoneal administration of a single dose of CP 
(200  mg/kg  body  weight)  induced  severe  biochemical  changes  as  well  as 
oxidative damage in cardiac tissue. There was a significant (P < 0.05) rise in the 
levels of diagnostic marker enzymes (CPK, LDH, AST and ALT) in the serum of 
Group II CP administered rats as compared to that of Group I control rats (Table 
1). The administration of Ficus hispida leaf extract to Group IV animals restored 
the levels of these enzymes to near normalcy (P < 0.05) as compared to those 
Group II CP-injected rats. In F. hispida alone administered rats (Group III) versus 
controls, no significant changes were observed. 
Effect of Ficus hispida on the levels of cardiac enzymes
In CP administered rats (Group II), the increase in serum marker enzyme 
activities was accompanied by concomitant decreased activities (P  < 0.05) of 
these enzymes in the heart tissue (Table 2), which depict the damage of heart in 
Group II animals. Activities of these enzymes in the cardiac tissue were restored 
to near normal levels (P < 0.05) in F.hispida treated rats (Group IV). This may be 
due to the protection offered by F.  hispida against tissue damage and oxidative 
stress induced by cyclophosphamide.
Effect of Ficus hispida on the levels of GSH and MDA in cardiac tissue
Injection of CP induced a significant (P < 0.05) increase in the level of lipid 
peroxidation (LPO), measured in terms of MDA (Fig. 8), which was paralleled by 
significant (P < 0.05) reduction in the level of GSH (Fig. 7) in the heart tissue of 
Group II animals as compared to normal controls. Glutathione plays an important 
role  in  the  regulation  of  variety  of  cell  functions  and  in  cell  protection  from 
oxidative injury.  Depletion of GSH results in enhanced lipid  peroxidation,  and 
excessive  lipid  peroxidation  can  cause  increased  GSH  consumption,  as 
observed in the present study. In this study, the treatment with F. hispida (Group 
IV) significantly (P <  0.05) counteracted the CP-induced lipid peroxidation and 
restored the level of GSH to near normal level in Group IV rats as compared to 
that of Group II animals.
Effect of Ficus hispida on the levels of cardiac tissue antioxidants
Activities of glutathione-dependent antioxidant enzymes (GPx, GST and 
GR) and anti-peroxidative enzymes (SOD and CAT) were significantly (P < 0.05) 
lower  in the heart  tissue of Group II  CP-injected rats  as compared to that  of 
Group I normal control rats (Table 3). The observed reduction in the activities of 
GPx, GR and GST in CP-induced myocardial damage might be due to decreased 
availability of its substrate, reduced glutathione (GSH). In the present study, the 
treatment of Group IV rats with  F.  hispida, significantly (P <  0.05) reversed all 
these CP-induced alterations in the activities of antioxidant enzymes (SOD, CAT, 
GPx, GST and GR) to a near normal status. The normal rats receiving F. hispida 
alone  (Group  III)  did  not  show  any  significant  change  when  compared  with 
control rats, indicating that it does not per se have any adverse effects.
Effect of Ficus hispida on the levels of serum TNF-α and NO
Fig. 9 and Fig.10 illustrate the serum levels of TNF-α and NO respectively.  
There was a significant (P < 0.05) rise in the levels of TNF-α and NO in the 
serum  of  CP  intoxicated  rats  as  compared  to  that  of  control  rats.  The 
administration  of  Ficus hispida leaf  extract  to  Group IV animals  restored the 
levels of these enzymes to near normalcy (P < 0.05). 
HISTOPATHOLOGICAL STUDIES (Plate 3)
A. Control (T.S.)
► Section depicts normal architecture of myocytes.
B. Cyclophosphamide-Induced (T.S.)
► Section depicts abnormal cardiac muscle with karyorrhexis,  
    pyknotic nuclei and leucocytic infiltration.   
C. Ficus hispida alone (T.S.)
► Section depicts almost normal architecture.
D. Cyclophosphamide + Ficus hispida treated (T.S.)
► Section depicts a significant recovery in the cardiac fibres. 
DISCUSSION
High-dose cyclophosphamide was introduced as a mainstay of numerous 
preparative regimens for haemopoietic stem-cell transplantation and its potential 
to cause myocardial damage was soon recognized. Santos et al.43 reported the 
first human fatality of cyclophosphamide (CP) cardiotoxicity as a complication of 
bone  marrow  transplantation.  Several  studies  implicate  that  high-dose 
cyclophosphamide  is  associated  with  cardiotoxicity.92-94  The  pharmacokinetics 
and metabolism of CP have been extensively studied.95 CP requires bioactivation 
to  form  4-hydroxy-CP  and  also  aldophosphamide,  which  spontaneously 
degrades  by  β-elimination,  to  form  stoichiometric  amounts  of  phosphoramide 
mustard and the toxic by-product acrolein.96 Acrolein is a highly reactive α, β-
unsaturated  aldehyde,  and  its  formation  from  CP was  first  demonstrated  by 
Alarcon and Meienhofer. 
The  aetiopathogenesis  of  CP  induced  cardiotoxicity  is  not  yet  fully 
unraveled. However, toxicity of CP was postulated to be mediated by oxidative 
stress48 which may have deleterious effects on the heart. Moreover, it is thought 
to involve direct endothelial damage, with extravasation of plasma proteins, high 
concentration  of  cyclophosphamide  and  erythrocytes  into  the  myocardial 
interstitium and muscle cells, resulting in damage of myocardial cells.97,98 Due to 
the damage, the enzymes (CPK, LDH, AST and ALT) leak from the necrotic  
heart cells to the serum, which are important measures of cardiac injury. These 
enzymes are not specific for myocardial injury individually; however, evaluation of 
these  enzymes  together  may  be  an  indicator  of  myocardial  injury.  In  CP-
administered rats, the activities of these marker enzymes were elevated in serum 
with a concomitant decrease in the heart tissue. FH treated rats showed near 
normalcy  in  these  enzyme  levels.  This  might  be  attributed to  the  membrane 
stabilizing  effect  of  the  phytoconstituents  like  oleanolic  acid  and  β-sitosterol, 
present in the FH51,99.
Reactive oxygen/nitrogen species (ROS/RNS) include superoxide anion, 
hydroxyl  radical,  alkoxyl  radical,  peroxyl  radical,  hydrogen  peroxide, singlet 
oxygen,  nitric  oxide  and peroxynitrite.  Superoxide  anion itself  is  not  a  strong 
oxidant, but it reacts with protons in water solution to form hydrogen peroxide 
(H2O2), which can serve as a substrate for the generation of hydroxyl radicals and 
singlet oxygen. The prevalent free radical states, or so-called oxidative stress, 
initiate the oxidation of polyunsaturated fatty acids (PUFA), proteins, DNA, and 
sterols.  The  reaction  of  nitric  oxide  (NO)  with  superoxide  anion  forms 
peroxynitrite,100 a potent cytotoxic oxidant eliciting lipid peroxidation and cellular 
damage.101 Thus,  free  radicals  generated  through  cyclophosphamide 
metabolism,  cause  membrane  damage  by  initiating  LPO  which  leads  to 
impairment in the integrity and function of myocardial membranes. The obtained 
data reveal that CP exposure produced a marked oxidative impact as reflected 
by elevated LPO, measured in terms of MDA level in the heart tissue. FH treated 
rats showed decreased MDA level, due to significant inhibition of LPO which is in  
line with earlier studies49. This might be due to the presence of oleanolic acid, 
hispidin  and  β-sitosterol  which  have been  reported  to  possess  anti-lipid 
peroxidation and/or free radical scavenging properties. 
TNF-α, the principal cytokine that mediates acute inflammation after high 
dose CP administration, was reduced by Ficus hispida treatment, which indicates 
its protective effect against CP-induced inflammation. Earlier, it was documented 
that  FH  exert  effective  anti-inflammatory  activity.66 The  presence  of 
phenanthroindolizidine alkaloids and other phytoconstituents might be attributed 
for the activity. 
Cells are equipped with an impressive repertoire of antioxidant defensive 
system. The present study shows that the free radical-induced increase in LPO is 
accompanied by concomitant decline in the activities of cellular antioxidants. This 
may be due to the inactivation of cellular antioxidants by lipid  peroxides and 
ROS. SOD is inhibited by hydrogen peroxide (H2O2) while GPx and CAT by an 
excess of superoxide radical. In fact,  the heart  has a greater susceptibility to 
oxidative stress than other tissues due to its inherent decreased detoxifying. The 
decrease  in  endogenous  antioxidant  enzymes  might  predispose  the  cardiac 
tissue to increased free radical damage, because SOD catalyzes the dismutation 
of superoxide anion to hydrogen peroxide, while CAT and GPx are involved in 
cellular detoxification and can convert H2O2 into water and oxygen. GPx is the 
most important hydrogen peroxide-removing enzyme existing in the membrane. If 
the activity of CAT or GPx is not adequate to degrade H2O2, more H2O2 could be 
converted  to  toxic  hydroxyl  radicals  and  may  contribute  to  the  CP–induced 
oxidative stress. Administration of FH replenished the antioxidant levels, which 
might  attributed  to  the  free  radical  scavenging/antioxidant  properties  of  its 
phytoconstituents described elsewhere in this report.  
Reduced glutathione (GSH), the first line of defense against ROS, is a 
readily available source of endogenous sulfhydryl  (-SH) groups. CP exposure 
caused a dramatic decline in GSH level, which may be ascribed to the direct 
conjugation  of  CP’s  metabolites  with  free  or  protein  bound  -SH  groups47,102, 
thereby interfering with the antioxidant functions. The activities of CAT, SOD and 
GPx were significantly reduced in GSH depleted condition due to pronounced 
oxidative stress and accumulation of H2O2, making the cells more vulnerable to 
oxidative stress. FH treatment restored the GSH level to near normalcy. One of 
the  reasons  for  this  restorative  effect  might  be  the  presence  of  triterpenoid 
constituents in FH.
CP  treated  rats  displayed  decreased  activities  of  GSH  metabolizing 
enzymes,  GST and GR which is  consistent  with  the previous report.103 Many 
investigators  have  suggested  that  GST  offers  protection  against  LPO  by 
promoting the conjugation of toxic electrophiles with GS. GR is a flavoprotein that  
permits the conversion of oxidized glutathione (GSSG) to reduced glutathione 
(GSH) by the oxidation of NADH to NAD+. Inactivation of GR in the heart, leads 
to  accumulation  of  GSSG which  in  turn  inactivates  enzymes  containing  -SH 
groups and inhibits protein synthesis. Impairment of these enzyme activities may 
thus be doubly detrimental to the myocardial tissue. F.hispida treatment restored 
the normal activities of these enzymes, thereby confirming its protective action. 
On histological examination, the cardiac sections from cyclophosphamide-
treated rats portrayed karyo-pyknosis of myocyte nuclei and leucocytic infiltration. 
F.hispida  treated  rats  exhibited  significant  recovery  from  cyclophosphamide-
induced myocardial damage, presenting a normal cardiac architecture.
Previous studies suggest that oleanolic acid has protective effect against 
cyclophosphamide-induced toxicities.54 Recent evidence suggests that oleanolic 
acid  has  a  significant  cardioprotective  effect51.  Intriguingly,  literature  citations 
show  that  phytosterols  like  β-sitosterol  exert  antioxidant,  cardioprotective 
properties.104,105 A  recent  report  suggests  the  possibility  of  GSH replenishing 
effect  of  β-amyrin.106 Prodigious  amounts  of  literature  data  suggest  that 
triterpenoids, flavonoids, tannins possess significant antioxidant/cardioprotective 
effects.107-110 Hence, it is suggested that presence of the aforementioned active 
ingredients in F.hispida leaf extract might be responsible for the abrogation of CP 
elicited cardiotoxicity. 
SUMMARY AND CONCLUSION
To summarize,  the results of the present study indicate that cyclophosphamide 
exposure results in the pronounced oxidative stress and tissue damage. Administration of 
Ficus hispida leaf  extract  protects  the cardiac  tissue by scavenging the free  radicals, 
which  is  evidenced  by  the  normalization  of  the  biochemical  parameters.  These 
observations support the hypothesis that Ficus hispida has potential for its evaluation as a 
cardioprotective agent against CP-induced oxidative myocardial  injury.  Further studies 
for  the  protective  role  of  Ficus  hispida in  cyclophosphamide-induced  toxicities  are 
currently under investigation. 
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